Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
140.56
-0.87 (-0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sarepta Therapeutics
< Previous
1
2
3
Next >
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
May 18, 2023
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Via
MarketBeat
Exposures
Product Safety
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
May 16, 2023
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.
Via
MarketBeat
Exposures
Product Safety
Sarepta Therapeutics Inc. (NASDAQ: SRPT) Leading the Way in Monday Trading Based on Percentage Gain
May 15, 2023
Via
Investor Brand Network
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
May 12, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
May 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 28, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
April 25, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Fox, Charles River, Provident, and Sarepta and Encourages Investors to Contact the Firm
April 17, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
April 10, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shareholder Notice: Investigation over Potential Securities Laws Violations
April 10, 2023
San Diego, CA -- (SBWIRE) -- 04/10/2023 -- Sarepta Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
April 10, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
April 09, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
April 02, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
SAREPTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sarepta Therapeutics, Inc. on Behalf of Sarepta Stockholders and Encourages Investors to Contact the Firm
March 29, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT
March 24, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
March 23, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) Investigation
March 21, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Why did Sarepta Therapeutics Stock Plummet?
March 21, 2023
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Via
MarketBeat
Exposures
Product Safety
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
March 16, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
March 16, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
February 28, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
February 28, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
February 21, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
February 17, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
January 05, 2023
From
Catalent, Inc.
Via
Business Wire
Is Pfizer Stock Still Worth Buying After the Pandemic?
October 12, 2022
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.
Via
MarketBeat
Exposures
COVID-19
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
A Trio of Q3 Winners With Room to Run
September 29, 2022
It's those rare bright spots in a dim market that can be the best places to hide. Here are three Q3 outperformers that still have good upside.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
Interest Rates
US Equities
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.